+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 1 Actively Recruiting clinical trials

E

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the PAC-Man model, an integrated differentiated service delivery approach designed to eliminate mother-to-child transmission of HIV in Malawi. This study compares the PAC-Man model to the standard care currently provided by the Ministry of Health. The trial aims to measure the effect of the PAC-Man model on timely early infant diagnosis testing and guideline-adherent viral load testing among pregnant and breastfeeding women living with HIV. It also assesses implementation outcomes of these strategies using a hybrid effectiveness-implementation stepped-wedge design across 12 health facility sites grouped into four clusters. The PAC-Man model includes three key evidence-based practices delivered via mobile care teams in community settings pediatric active case finding using novel point-of-care early infant diagnosis technology, same-day antiretroviral therapy initiation for infants newly diagnosed with HIV, and maternal viral load testing with back-to-care services. These mobile teams deploy diagnostic technology called m-PIMA and use task shifting, where community health workers and nurses provide services at convenient community locations to improve access and adherence. The intervention is compared against routine care provided by the Ministry of Health. Participants include mother-infant pairs enrolled in the national EMTCT program, high-risk pregnant or breastfeeding women with HIV, healthcare providers, and policy makers. Data collection involves surveys, interviews, focus groups, and implementation actor questionnaires. The study measures include the proportion of infants receiving early infant diagnosis by six months, viral load testing for mothers, ART initiation rates, and retention in care. Outcomes are tracked within 12 months of enrollment, and implementation costs and adoption rates are also evaluated. The trial is conducted under routine care conditions and runs until March 2028.

Age: 16Years +All GendersPhase Not Applicable
3 locations